Scholarlink

Background <p>Metabolic syndrome (MetS), a cluster of metabolic abnormalities, has been increasingly linked to hormone-related cancers, including endometrial cancer (EC). However, the overall magnitude and consistency of this association remain unclear. We performed a meta-analysis to evaluate whether MetS is associated with an increased incidence of EC in women.</p> Methods <p>PubMed, Embase, and Web of Science were systematically searched from inception to June 8, 2025. Eligible studies were longitudinal cohort or nested case-control studies that reported the association between baseline MetS and incident EC in the general female population. Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled using a random-effects model accounting for possible influence of heterogeneity.</p> Results <p>Nine studies involving 11 datasets and over 9.1&#xa0;million women were included. MetS was associated with a significantly increased risk of EC (pooled RR = 2.00, 95% CI: 1.67–2.40, <i>p</i> &lt; 0.00001; I² = 93%). The association was stronger in prospective cohort and nested case-control studies (RR = 2.30 and 2.02, respectively) than in retrospective cohort studies (RR = 1.42; <i>p</i> for subgroup difference &lt; 0.001). The results were not significantly affected by menopausal status of the women, diagnostic criteria of MetS, follow-up durations, EC validation methods, or study quality scores (<i>p</i>-values for subgroup difference all &gt; 0.05).</p> Conclusions <p>MetS is associated with a two-fold increased risk of EC in women. These findings underscore the importance of metabolic health management in strategies for EC prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The association between metabolic syndrome and incidence of endometrial cancer: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Junyan Zhong,
  • Binbin Cai,
  • Tingting Su,
  • Haobo Chen

摘要

Background

Metabolic syndrome (MetS), a cluster of metabolic abnormalities, has been increasingly linked to hormone-related cancers, including endometrial cancer (EC). However, the overall magnitude and consistency of this association remain unclear. We performed a meta-analysis to evaluate whether MetS is associated with an increased incidence of EC in women.

Methods

PubMed, Embase, and Web of Science were systematically searched from inception to June 8, 2025. Eligible studies were longitudinal cohort or nested case-control studies that reported the association between baseline MetS and incident EC in the general female population. Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled using a random-effects model accounting for possible influence of heterogeneity.

Results

Nine studies involving 11 datasets and over 9.1 million women were included. MetS was associated with a significantly increased risk of EC (pooled RR = 2.00, 95% CI: 1.67–2.40, p < 0.00001; I² = 93%). The association was stronger in prospective cohort and nested case-control studies (RR = 2.30 and 2.02, respectively) than in retrospective cohort studies (RR = 1.42; p for subgroup difference < 0.001). The results were not significantly affected by menopausal status of the women, diagnostic criteria of MetS, follow-up durations, EC validation methods, or study quality scores (p-values for subgroup difference all > 0.05).

Conclusions

MetS is associated with a two-fold increased risk of EC in women. These findings underscore the importance of metabolic health management in strategies for EC prevention.